Organocatalysis for Asymmetric Synthesis: From Lab To Factory

Sustainable Catalysis: Challenges and Practices for the Pharmaceutical and Fine Chemical Industries

Volumn , Issue , 2013, Pages 317-337

  Xu, Feng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asymmetric synthesis; MK 8613 synthesis; Organocatalysis; Telcagepant synthesis

Indexed keywords

EID: 84886118976     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118354520.ch14     Document Type: Chapter

References (69)

1. Ahrendt KA, Borths CJ, MacMillan DWC (2000). New strategies for organic catalysis: the first highly enantioselective organocatalytic Diels-Alder reaction. J. Am. Chem. Soc. 122, 4243- 4244.
2. For recent reviews, see The preceding chapter authored by Y. Hayashi in this book.
3. Marqués-López E, Herrera RP, Christmann M (2010). Asymmetric organocatalysis in total synthesis-a trial by fire. Nat. Prod. Rep. 27, 1138-1167.
4. Valero G, Companyo X, Bravo N, Alba ANR, Moyano A, Rios R (2010). Searching for untrodden paths in the organocatalysis territory. Synlett 1883-1908.
5. Bertelsen S, Jørgensen KA (2009). Organocatalysis-after the gold rush. Chem. Soc. Rev. 38, 2178-2189.
6. Enders D, Narine AA (2008). Lessons from nature: biomimetic organocatalytic carbon-carbon bond formations. J. Org. Chem. 73, 7857- 7870.
7. MacMillan DWC (2008). The advent and development of organocatalysis. Nature 455, 304-308.
8. Walji AM, MacMillan DWC (2007). Strategies to bypass the taxol problem. Enantioselective cascade catalysis, a new approach for the efficient construction of molecular complexity. Synlett 1477-1489.
9. Gaunt MJ, Johansson CCC, McNally A, Vo NT (2007). Enantioselective organocatalysis. Drug Discovery Today, 12, 8-27.
10. Moyano A, Rios R (2011). Asymmetric organocatalytic cyclization and cycloaddition reactions. Chem. Rev. 111, 4703-4832.
11. Prelog V, Wihelm M (1954). Untersuchungen über asymmetrische synthesen VI. Der reaktionsmechanismus und der sterische verlauf der asymmetrischen cyanhydrin-Synthese. Helv. Chim. Acta 37, 1634-1660.
12. List B, Lerner RA, Barbas, III, CF (2000). Proline-catalyzed direct asymmetric aldol reactions. J. Am. Chem. Soc. 122, 2395-2396.
13. Few examples of asymmetric organocatalysis on large scale were reported prior to the 'gold rush' of organocatalysis. For application of enamine organocatalysis, see (a) Eder U, Sauer G, Weichert R, inventors. Optically active 1,5-indandione and 1,6-naphthalenedione derivatives. German Patent DE2014757 1971.
14. Eder U, Sauer G, Weichert R (1971). New type of asymmetric cyclization to optically active steroid CD partial structures. Angew. Chem., Int. Ed. 10, 496-497.
15. Hajos ZG, Parrish DR, inventors. Asymmetric synthesis of optically active polycyclic organic compounds. German Patent DE2102623 1971.
16. Hajos ZG, Parrish DR (1974). Asymmetric synthesis of bicyclic intermediates of natural product chemistry. J. Org. Chem. 39, 1615-1621.
17. For a practical, asymmetric phase-transfer catalyzed alkylation, see (e) Dolling UH, Davis P, Grabowski EJJ (1984). Efficient catalytic asymmetric alkylations: 1. Enantioselective synthesis of (+)-indacrinone via chiral phase-transfer catalysis. J. Am. Chem. Soc. 106, 446-447.
18. Hughes DH, Dolling UH, Ryan KM, Schoenewaldt EF, Grabowski EJJ (1987). Efficient catalytic asymmetric alkylations. 3. A kinetic and mechanistic study of the enantioselective phase-transfer methylation of 6,7-dichloro-5-methoxy-2-phenyl-1-indanone. J. Org. Chem. 52, 4745-4752.
19. Bhattacharya A, Dolling UH, Grabowski EJJ, Karady S, Ryan KM, Weinstock LM (1986). Enantioselective Robinson annelations via phase-transfer catalysis. Angew. Chem., Int. Ed. 25, 476-477.
20. For detailed mechanistic studies of enamine catalysis, see (a) Hoang L, Bahmanyar S, Houk KN, List B (2003). Kinetic and stereochemical evidence for the involvement of only one proline molecule in the transition states of proline-catalyzed intra- and intermolecular aldol reactions. J. Am. Chem. Soc. 125, 16-17.
21. For early examples of enamine catalysis, see (b) Woodward RB, Logusch E, Nambiar KP, Sakan K, Ward DE, Au-Yeung BW, Balaram P, Browne LJ, Card PJ, Chen CH, ChBnevert RB, Fliri A, Frobel K, Gais HJ, Garratt DG, Hayakawa K, Heggie W, Hesson DP, Hoppe D, Hoppe I, Hyatt JA, Ikeda D, Jacobi PA, Kim KS, Kobuke Y, Kojima K, Krowicki K, Lee VJ, Leutert T, Malchenko S, Martens J, Matthews RS, Ong BS, Press JB, Rajan Babu TV, Rousseau G, Sauter HM, Suzuki M, Tatsuta K, Tolbert LM, Truesdale EA, Uchida I, Ueda Y, Uyehara T, Vasella AT, Vladuchick WC, Wade PA, Williams RM, Wong HNC (1981). Asymmetric total synthesis of erythromycin: 1. Synthesis of an erythronolide A secoacid derivative via asymmetric induction. J. Am. Chem. Soc. 103, 3210-3213.
22. Danishefsky S, Cain P (1976). Optically specific synthesis of estrone and 19-norsteroids from 2,6-lutidine. J. Am. Chem. Soc. 98, 4975-4983.
23. Xu F, Zacuto M, Yoshikawa N, Desmond R, Hoerrner S, Itoh T, Journet M, Humphrey GR, Cowden C, Strotman N, Devine P (2010). Asymmetric synthesis of telcagepant, a CGRP receptor antagonist for the treatment of migraine. J. Org. Chem. 75, 7829-7841.
24. Xu F, Corley E, Zacuto M, Conlon DA, Pipik B, Humphrey G, Murry J, Tschaen D (2010). Asymmetric synthesis of a potent, aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV inhibitor. J. Org. Chem. 75, 1343-1353.
25. Keen SP, Cowden CJ, Bishop BC, Brands KMJ, Davies AJ, Dolling WH, Lieberman DR, Stewart GW (2005). Palladium-catalyzed allylic acyloxylation of terminal alkenes in the presence of a base. J. Org. Chem. 70, 1771-1779.
26. Scott JP, Ashwood MS, Brands KMJ, Brewer SE, Cowden CJ, Dolling UH, Emerson KM, Gibb AD, Goodyear A, Oliver SF, Stewart GW, Wallace DJ (2008). Development of a phase transfer catalyzed asymmetric synthesis for an estrogen receptor beta selective agonist. Org. Process Res. Dev. 12, 723-730.
27. For additional recent examples of application of phase-transfer catalyzed alkylation/addition, see (a) Huffman MA, Rosen JD, Farr RN, Lynch JE (2007). Synthesis of a selective estrogen receptor β-modulator via asymmetric phase-transfer catalysis. Tetrahedron 63, 4459-4463.
28. Jiang X, Gong B, Prasad K, Repič O (2008). A practical synthesis of a chiral analogue of FTY720. Org. Process Res. Dev. 12, 1164-1169.
29. For recent examples of organocatalytic desymmetrization, see (c) Yue TY, McLeod DD, Albertson KB, Beck SR, Deerberg J, Fortunak JM, Nugent WA, Radesca LA, Tang L, Xiang CD (2006). Stereoselective process for a CCR3 antagonist. Org. Process Res. Dev. 10, 262-271.
30. Mittendorf J, Benet-Buchholz J, Fey P, Mohrs KH (2003). Efficient asymmetric synthesis of β-aamino acid BAY 10-8888/PLD-118, a novel antifungal for the treatment of yeast infections. Synthesis 136-140.
31. Ishii Y, Fujimoto R, Mikami M, Murakami S, Miki Y, Furukawa Y (2007). Practical syntheses of chiral α-amino acids and chiral half-esters by kinetic resolution of urethane-protected α-amino acid N-carboxyanhydrides and desymmetrization of cyclic meso-anhydrides with new modified cinchona alkaloid catalysts. Org. Process Res. Dev. 11, 609-615.
32. For examples of organocatalytic epoxidation, see (f) Ager DJ, Anderson K, Oblinger E, Shi Y, VanderRoest J (2007). An epoxidation approach to a chiral lactone: application of the Shi epoxidation. Org. Process Res. Dev. 11, 44-51.
33. For selected recent leading examples, see (a) Ishikawa H, Suzuki T, Hayashi Y (2009). Highyielding synthesis of the anti-influenza neuramidase inhibitor (-)-oseltamivir by three "one-pot" operations. Angew. Chem., Int. Ed. 48, 1304-1307.
34. Simmons B, Walji AM, MacMillan DWC (2009). Cycle-specific organocascade catalysis: application to olefin hydroamination, hydrooxidation, and amino-oxidation, and to natural product synthesis. Angew. Chem., Int. Ed. 48, 4349-4353.
35. Zuend SJ, Coughlin MP, Lalonde MP, Jacobsen EN (2009). Scaleable catalytic asymmetric Strecker syntheses of unnatural α-amino acids. Nature 461, 968-971.
36. Jones SB, Simmons B, MacMillan DWC (2009). Nine-step enantioselective total synthesis of (+)-minfiensine. J. Am. Chem. Soc. 131, 13606-13607.
37. Goadsby PJ, Lipton RB, Ferrari MD(2002). Migraine-current understanding and treatment. N. Engl. J. Med. 346, 257-270.
38. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007). The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27, 193-210.
39. Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, Koblan KS, Salvatore CA, Mosser SD, Johnston VK, Wong BK, Miller-Stein CM, Hershey JC, Graham SL, Vacca JP, Williams TM (2007). Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2- oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide (MK-0974). J. Med. Chem. 50, 5564-5567.
40. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Asaid C, Lines C, Koppen H,Winner PK (2008). Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372, 2115- 2123.
41. Ho TW, Mannix L, Fanm X, Assaid C, Furtek C, Jones C, Lines C, Rapoport A (2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70, 1304-1312.
42. For early syntheses, see (a) Burgey CS, Paone DV, Shaw AW, Deng JZ, Nguyen DN, Potteiger SL, Graham SL, Vacca JP, Williams TM (2008). Synthesis of the (3R,6S)-3-amino-6-(2,3- difluorophenyl)azepan-2-one of telcagepant (MK-0974), a calcitonin gene-related peptide receptor antagonist for the treatment of migraine headache. Org. Lett. 10, 3235-3238.
43. Steinhuebel DP, Krska SW, Alorati A, Baxter JM, Belyk K, Bishop B, Palucki M, Sun Y, Davies IW (2010). Asymmetric hydrogenation of protected allylic amines. Org. Lett. 12, 4201-4203.
44. Baxter JM, Steinhuebel DP, Palucki M, Davies IW (2005). Stereoselective enol tosylation: preparation of trisubstituted α,β-unsaturated esters. Org. Lett. 7, 215-218.
45. Janey JM, Orella CJ, Njolito E, Baxter JM, Rosen JD, Palucki M, Sidler RR, Li W, Kowal JJ, Davies IW (2008). Raney-Co mediated reductive cyclization of an α,β-unsaturated nitrile. J. Org. Chem. 73, 3212-3217.
46. Palucki M, Davies I, Steinhuebel D, Rosen J, inventors; Merck & Co, Inc., assignee. Process for preparation of (3R,6S)-3-amino-6-(2,3-difluorophenyl)-1-(2,2,2-trifluoroethyl) azepan-2-one hydrochloride. World Patent WO/2007/120589. October 25, 2007.
47. Gotoh H, Ishikawa H, Hayashi Y (2007). Diphenylprolinol silyl ether as catalyst of an asymmetric, catalytic, and direct Michael reaction of nitroalkanes with α,β -unsaturated aldehydes. Org. Lett. 9, 5307-5309.
48. Palomo C, Landa A, Mielgo A, Oiarbide M, Pugel A, Vera S (2007). Water-compatible iminium activation: organocatalytic Michael reactions of carbon-centered nucleophiles with enals. Angew. Chem., Int. Ed. 46, 8431-8435.
49. Zu L, Xie H, Li H,Wang J,Wang W(2007). Highly enantioselective organocatalytic conjugate addition of nitromethane to α,β-unsaturated aldehydes: three-step synthesis of optically active baclofen. Adv. Synth. Catal. 349, 2660-2664.
50. Hojabri L, Hartikka A, Moghaddam FM, Arvidsson PI (2007). A new imidazole-containing imidazolidinone catalyst for organocatalyzed asymmetric conjugate addition of nitroalkanes to aldehydes. Adv. Synth. Catal. 349, 740-748.
51. Wang Y, Li P, Liang X, Zhang TY, Ye J (2008). An efficient enantioselective method for asymmetric Michael addition of nitroalkanes to α,β-unsaturated aldehydes. Chem. Commun. 1232-1234.
52. Marigo M, Wabnitz TC, Fielenbach D, Jørgensen KA (2005). Enantioselective organocatalyzed a sulfenylation of aldehydes. Angew. Chem., Int. Ed. 44, 794-797.
53. Hayashi Y, Gotoh H, Hayashi T, Shoji M (2005). Diphenylprolinol silyl ethers as efficient organocatalysts for the asymmetric Michael reaction of aldehydes and nitroalkenes. Angew. Chem., Int. Ed. 44, 4212-4215.
54. For an example of the acidity of PivOH and its interaction with amine bases, see Xu F, Armstrong, III, JD, Zhou GX, Simmons B, Hughes D, Ge Z, Grabowski EJJ (2004). Mechanistic evidence for an α-oxoketene pathway in the formation of β-ketoamides/esters via Meldrum's acid adducts. J. Am. Chem. Soc. 126, 13002-13009.
55. Edmondson SD, Mastracchio A, Cox JM, Eiermann GJ, He H, Lyons KA, Patel RA, Patel SB, Petrov A, Scapin G, Wu JK, Xu S, Zhu B, Thornberry NA, Roy RS, Weber AE (2009). Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorg. Med. Chem. Lett. 19, 4097-4101.
56. Cox JM, Edmondson SD, Harper B,Weber AE, inventors; Merck & Co, Inc., assignee. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes. World Patent WO/2006/039325. April 13, 2006.
57. Xu F, Corley E, Murry JA, Tschaen DM (2007). Highly selective cascade couplings for the syntheses of functionalized piperidinones and bispidines. Org. Lett. 9, 2669-2672.
58. One-pot synthesis led to a low yield of fluoro-substituted styrenes, see Jacobo R, Cota A, Rogel E, Garcia JD, Rivero IA, Hellberg LH, Somanathan R (1994). Synthesis of some fluorinated nitro-olefins. J. Fluorine Chem. 67, 253-255.
59. For examples, see (a) Terada M, Ube H, Yaguchi Y (2006). Axially chiral guanidine as enantioselective base catalyst for 1,4-addition reaction of 1,3-dicarbonyl compounds with conjugated nitroalkenes. J. Am. Chem. Soc. 128, 1454-1455.
60. Evans DA, Seidel D (2005). Ni(II)-bis[(R,R)-N,N0-dibenzylcyclohexane-1,2-diamine]Br2 catalyzed enantioselective Michael additions of 1,3-dicarbonyl compounds to conjugated nitroalkenes. J. Am. Chem. Soc. 127, 9958-9959.
61. Okino T, Hoashi Y, Furukawa T, Xu X, Takemoto Y (2005). Enantio- and diastereoselective Michael reaction of 1,3-dicarbonyl compounds to nitroolefins catalyzed by a bifunctional thiourea. J. Am. Chem. Soc. 127, 119-125.
62. Li H, Wang Y, Tang L, Deng L (2004). Highly enantioselective conjugate addition of malonate and β-ketoester to nitroalkenes: asymmetric C-C bond formation with new bifunctional organic catalysts based on cinchona alkaloids. J. Am. Chem. Soc. 127, 9906-9907.
63. Watanabe M, Ikagawa A, Wang H, Murata K, Ikariya T (2004). Catalytic enantioselective Michael addition of 1,3-dicarbonyl compounds to nitroalkenes catalyzed by well-defined chiral Ru amido complexes. J. Am. Chem. Soc. 126, 11148-11149.
64. Ji J, Barnes DM, Zhang J, King SA, Wittenberger SJ, Morton HE (1999). Catalytic enantioselective conjugate addition of 1,3- dicarbonyl compounds to nitroalkenes. J. Am. Chem. Soc. 121, 10215-10216.
65. Hynes PS, Stupple PA, Dixon DJ (2008). Organocatalytic asymmetric total synthesis of (R)-rolipram and formal synthesis of (3S,4R)-paroxetine. Org. Lett. 10, 1389-1391.
66. Zhu Q, Huang H, Shi D, Shen Z, Xia C (2009). An efficient synthesis of chiral diamines with rigid backbones: application in enantioselective Michael addition of malonates to nitroalkenes. Org. Lett. 11, 4536-4539.
67. For a recent review, see Palomo C, Oiarbide M, López R (2009). Asymmetric organocatalysis by chiral Brønsted bases: implications and applications. Chem. Soc. Rev. 38, 632-653.
68. Li H, Wang Y, Tang L, Wu F, Liu X, Guo C, Foxman BM, Deng L (2005). Stereocontrolled creation of adjacent quaternary and tertiary stereocenters by a catalytic conjugate addition. Angew. Chem., Int. Ed. 44, 105-108.
69. Zacuto MJ, Xu F (2007). One-step RhCl3-catalyzed deprotection of acyclic N-allyl amides. J. Org. Chem. 72, 6298-6300.